TNFα Blockade With Checkpoint Inhibitors for Cancer Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immune checkpoint inhibitors like anti-PD-1 show limited efficacy in treating cancer, with 60-67% of patients not responding and severe immune-related adverse events, while TNF signaling impairs CD8+ T cell responses, contributing to tumor progression.
Innovation Solution
Combining a TNFα blocking agent with immune checkpoint inhibitors, such as anti-CTLA-4 and PD-1 antibodies, to enhance CD8+ T cell activity and overcome TNF-induced immune suppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint inhibitors like anti-PD-1 are used to treat cancer, then tumor response rate improves, but a significant proportion of patients experience tumor relapse and severe immune-related adverse events
Solution Approach 1:
The patent combines anti-PD-1 immune checkpoint inhibitor with anti-TNF blocking agent in a dual-therapy regimen. This merging of two different therapeutic mechanisms (checkpoint inhibition and cytokine blockade) aims to achieve synergistic anti-tumor effects while reducing relapse and adverse events by addressing multiple immune suppression pathways simultaneously
Solution Approach 2:
The patent introduces anti-TNF blocking agent as an intermediary that modulates the immune microenvironment. By blocking TNF signaling, this intermediary agent prevents TNF-induced immune suppression and protects CD8+ T cells from activation-induced cell death, thereby enhancing the overall efficacy and safety of the immune checkpoint inhibitor
2Stability of the object's composition
If TNF signaling is active in the host, then immune response regulation is maintained, but CD8+ T cell-dependent immune response against melanoma is impaired
Solution Approach 1:
The patent extracts and blocks the harmful TNF signaling pathway from the immune system using anti-TNF blocking agents. By specifically targeting and neutralizing TNF, the therapy removes the suppressive influence on CD8+ T cells while preserving other essential immune regulatory mechanisms
Solution Approach 2:
The patent changes the parameter of TNF signaling activity from active to blocked state. By administering anti-TNF blocking agents, the therapy alters the biochemical parameter of TNF-receptor interaction, thereby converting the immunosuppressive environment into an immunostimulatory one that enhances CD8+ T cell function
Data Source
AI summary
The present invention relates to methods and pharmaceutical composition for the treatment of cancer. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount of a TNFα blocking agent to a subject in combination with the immune checkpoint inhibitor.